abstract |
The present disclosure relates to a novel course of treatment for patients with inflammatory arthritis, such as rheumatoid arthritis (RA), such as high-risk RA patients, which utilizes a therapeutically effective amount of an IL-17 antagonist, such as IL -17 binding molecules (such as IL-17 antibodies or antigen-binding fragments thereof, such as secukinumab) or IL-17 receptor binding molecules (such as IL-17 antibodies or antigen-binding fragments thereof). |